IRCT2013042213090N1已完成未知
Efficiency of enalapril in the protection of Anthracycline-induced cardiomyophy in cancer patients undergoing chemotheraphy compared with control group in Toba clinic in 2013-2014
Vice chancellor for research, Mazandaran University of Medical Sciences0 个研究点开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 70 years（—）
- 性别
- All
入选标准
- •patients aged between 18-70 years old; new diagnosed cancer patients that should be underwent antracyclin therapy.
- •Exclusion criteria: history of myocardial infarction or coronary artery disease; LVEF<50%; significant valvular heart disease; history of congestive heart failure; renal failure with glomerular filteration rate of less than 30ml/h; history of allergy to ACEI and systolic blood pressure less than 90 mmHg.
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Efficiency of carvedilol in the protection of Anthracycline-induced cardiomyophy in cancer patients undergoing chemotheraphy compared with control groupCancer.Malignant NeoplasmsC00-C97IRCT2014121213090N2Vice Chancellor for research of Mazandaran University of Medical Sciences80
已完成
2 期
Evaluation of the effect of Enalapril on endothelial dysfunction and improvement of clinical status in migraineursMigraine.Diseases of the nervous system/Episodic and paroxysmal disordersIRCT138711011570N1Isfahan University of Medical Sciences, Applied Physiology Research Center40
进行中（未招募）
1 期
Study of the antiresorptive treatment with alendronate versus no treatment after denosumab and aromatase inhibitors discontinuation in low fracture risk osteopenic postmenopausal women with non metastatic hormonal receptor positive breast cancer.EUCTR2020-005343-23-ITIRCCS ISTITUTO ORTOPEDICO GALEAZZI S.P.A190
已完成
不适用
comparative of the effects of Atenolol, Enalapril and HydrochlorothiazidHypertension.Hypertensive heart disease without (congestive) heart failureIRCT2012110511371N1Ardabil University of Medical Sciences150
尚未招募
1 期
The effect of combination of valproic acid and anti-tumor drug on pancreatic and biliary cancerunresectable or reccurrent pancreatic cancer and biliary cancer (20 patients)JPRN-UMIN000004525Department of surgery, Tokushima university hospital20